Page 46 - Read Online

Paridar et al. J Cancer Metastasis Treat 2017;3:38-44 Journal of
DOI: 10.20517/2394-4722.2016.61
Cancer Metastasis and Treatment

www.jcmtjournal.com
Review Open Access

Cytogenetic and molecular basis of

BCR-ABL myelodysplastic syndrome:

diagnosis and prognostic approach

Mostafa Paridar, Omid Kiani Ghalesardi, Mohammad Seghatoleslami, Ahmad Ahmadzadeh, Abbas Khosravi,
Najmaldin Saki
Health Research Institute, Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61357-15794, Iran.

Correspondence to: Dr. Najmaldin Saki, Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur
University of Medical Sciences, Ahvaz 61357-15794, Iran. E-mail: najmaldinsaki@gmail.com

How to cite this article: Paridar M, Ghalesardi OK, Seghatoleslami M, Ahmadzadeh A, Khosravi A, Saki N. Cytogenetic and molecular basis of
BCR-ABL myelodysplastic syndrome: diagnosis and prognostic approach. J Cancer Metastasis Treat 2017;3:38-44.
ABSTRACT
Article history: Myelodysplastic syndromes (MDS) include a heterogeneous group of blood disorders
Received: 31-10-2016 generally afflicting older people. Several genetic factors have been reported from these
Accepted: 12-01-2017 patients that have an important role in the diagnosis, prognosis, and treatment of this
Published: 28-02-2017 disease. BCR-ABL1 is a genetic factor that has occasionally been reported in some studies.
This review attempts to characterize MDS patients reported to harbor this fusion and to
Key words: assess the diagnostic, therapeutic, and prognostic potential of BCR-ABL1 fusionin MDS
Myelodysplastic syndrome, patients. This review showed that BCR-ABL fusion has been reported in 22 MDS patients
cytogenetics, whose condition generally transformed to acute myeloblastic leukemia and was not
BCR-ABL
responsive to conventional therapies. However, these patients showed a good response to
treatment with tyrosine kinase inhibitors. Therefore, even though incidence of BCR-ABL
fusion appears to be low in MDS patients, its detection is essential in assessing disease
prognosis and choosing appropriate treatment.

INTRODUCTION AML patients, and the remaining two-thirds succumb
to progressive BM failure, which leads to bleeding,
Myelodysplastic syndromes (MDS) are a group of clonal frequent infections, and severe anemia. MDS is
[3]
myeloid disorders with morphological characteristics generally an adult disease with an average age upon
such as hypercellular bone marrow (BM), single- or diagnosis of 65-70 years; less than 10% of patients are
multilineage dysplasia, and cytopenia in peripheral younger than 50 years. The annual incidence rate of
blood (PB). [1,2] Mortality associated with cytopenia MDS is approximately 5 cases per 100,000 population;
and risk of transformation to acute myeloblastic incidence increases to 22-45 cases per 100,000
leukemia (AML) are important problems for MDS in people over 70 years of age. MDS is generally
[4]
patients. In fact, one-third of MDS patients become diagnosed by accurate assessment of PB followed by

Quick Response Code:
This is an open access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work
non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: service@oaepublish.com

38 © 2017 OAE Publishing Inc. www.oaepublish.com